Zhi Tong Cai Jing·2025-11-17 08:52Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the marketing of fumaric acid volnorex, indicating a significant advancement in its product portfolio and potential revenue growth in the pharmaceutical market [1] Company Summary - Shandong Xinhua Pharmaceutical submitted the registration application for fumaric acid volnorex in March 2024, which was accepted by the National Medical Products Administration [1] - The company received the approval notice for the chemical raw material drug in November 2025, allowing it to commence production [1] Industry Summary - Fumaric acid volnorex is primarily used for treating gastroesophageal reflux disease and is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The sales revenue for fumaric acid volnorex-related formulations in Chinese public medical institutions is projected to be approximately RMB 825 million in 2024 [1]